Randomised Controlled Trials (RCTs) have long been hailed as the gold standard of evidence for medicine. They promise objectivity: randomly assign participants to treatment or control groups, minimise bias, and let the data speak. Yet as scrutiny intensifies into how pharmaceutical giants actually operate, a more troubling picture emerges. Far from pure science, RCTs and the broader clinical trial ecosystem are frequently shaped, massaged, and sometimes outright gamed, to favour commercial outcomes. The result is a system that delivers profits more reliably than breakthroughs, leaving patients and doctors navigating evidence that may be less reliable than advertised, and this is relevant to our health.
The article from Vigilant Fox (linked below), lays bare some of the core mechanics. Big Pharma doesn't just fund the majority of trials: it designs them, controls the data, and often decides what sees the light of day. This creates inherent conflicts. Positive results drive approvals, stock prices, and blockbuster sales. Negative or ambiguous ones? They can be buried, reframed, or spun through selective reporting. Consider the subtle tricks: endpoint switching, where primary measures are quietly altered mid-trial if initial goals falter; short trial durations that mask long-term risks or waning efficacy; and narrow patient populations that inflate success rates before real-world use exposes limitations. "Statistical significance" can be chased through massive sample sizes while clinical meaningfulness, actual patient benefit, takes a backseat.
Even randomisation and blinding, the pillars of RCT integrity, face pressure. Industry-funded trials are more likely to report favourable outcomes, a pattern documented across therapeutic areas. Ghost-writing, where company-hired medical writers draft papers credited to academic "authors," further polishes the narrative. Journals, reliant on pharma advertising and reprints, have their own incentives. The entire pipeline, from trial registration to publication, can resemble a carefully orchestrated marketing campaign rather than disinterested inquiry. Regulators like the FDA, while rigorous on some fronts, operate within a system where user fees from industry fund large portions of review processes, creating another layer of dependency.
The limits of RCTs themselves compound these issues. They excel at isolating specific effects under ideal conditions, but struggle with real-world complexity: comorbidities, long-term outcomes, diverse populations, and subtle harms. Many pivotal trials exclude the very patients who will eventually take the drug: the elderly, those with multiple conditions, or from varied ethnic backgrounds. Post-market surveillance often reveals problems RCTs missed, yet getting drugs to market first remains the priority. "Evidence-based medicine" risks becoming "pharma-selected evidence" medicine when negative data vanishes into file drawers or is reframed as "failed trials" rather than informative ones.
One of the most significant limitations concerns external validity. An RCT may reveal what happens under highly controlled conditions, but real patients rarely resemble trial participants. Individuals with multiple chronic conditions are often excluded. Elderly patients may be underrepresented. Those taking numerous medications are frequently screened out. Researchers seek homogeneity to reduce statistical noise, but in doing so may create study populations that bear only a limited resemblance to the patients who eventually receive the treatment.
As a result, a therapy shown to be effective in carefully selected volunteers may perform very differently in ordinary clinical practice. The trial answers one question while clinicians face another. The distinction is often overlooked.
The RCT also struggles with complexity. It works best when investigating a relatively simple intervention aimed at a relatively simple outcome. Modern health problems are often neither. Obesity, depression, chronic pain, autoimmune disorders, and dementia emerge from complex interactions involving genetics, environment, behaviour, nutrition, stress, and social circumstances. Attempting to isolate a single causal factor may illuminate part of the picture while obscuring the larger whole.
Nutrition research illustrates the problem. It is difficult to randomise entire diets over many years, while controlling for countless lifestyle variables. Consequently, some of the most important health questions resist the methodological strengths of the RCT. The result is a paradox: the interventions most amenable to randomised trials are often pharmaceutical, while broader lifestyle and environmental factors may remain comparatively understudied despite potentially exerting larger effects.
Cost introduces another distortion. Large, high-quality trials are expensive. This reality creates an inevitable funding bias. Pharmaceutical companies can afford to finance studies on patentable drugs because successful outcomes may generate substantial profits. There is far less financial incentive to fund large trials investigating inexpensive interventions, dietary changes, exercise programs, sunlight exposure, or other measures that cannot easily be patented. The absence of evidence is then mistaken for evidence of absence.
Publication bias compounds the problem. Positive studies are more likely to be published than negative ones. Journals favour statistically significant findings. Researchers face career incentives that reward novel discoveries rather than null results. Consequently, the scientific literature may present a distorted picture in which successful interventions appear more successful than they actually are.
Even within published trials, statistical manipulation remains a concern. Outcomes may be changed after data collection begins. Subgroup analyses can generate apparently impressive findings that disappear upon replication. Relative risk reductions may be emphasised while absolute risk reductions receive little attention. A treatment that reduces risk from two percent to one percent can be advertised as reducing risk by fifty percent, despite the absolute benefit being only one percentage point.
The replication crisis has further undermined confidence in the assumption that publication alone guarantees reliability. Across psychology, medicine, and other sciences, numerous findings have proven difficult or impossible to reproduce. The RCT is not immune to the broader challenges affecting modern scientific research.
Another neglected issue concerns individuality. Randomised trials produce population averages. They tell us what tends to happen across groups. Patients, however, are not averages. A treatment that provides modest benefit on average may be highly effective for some individuals and ineffective or harmful for others. Precision medicine emerged partly in response to this limitation, recognising that biological diversity can profoundly influence treatment outcomes.
There are also ethical constraints. Some questions cannot be answered through randomisation. Researchers cannot ethically assign people to smoke cigarettes for decades to determine whether smoking causes cancer. Nor can they randomly expose populations to environmental toxins, poverty, or trauma. Many important insights therefore emerge from observational studies, natural experiments, epidemiology, and mechanistic reasoning rather than from RCTs.
History offers numerous examples where evidence outside the RCT framework proved decisive. The link between smoking and lung cancer was established primarily through observational evidence. The dangers of asbestos, lead exposure, and numerous occupational hazards became apparent long before randomised trials could have been contemplated. To dismiss such evidence merely because it is not randomised would be absurd.
The deeper philosophical issue concerns the nature of causation itself. The RCT is often presented as the closest thing science possesses to a causal machine. Yet causation in biology is rarely simple. Human beings are complex adaptive systems. Multiple causes interact across different levels of organisation. Statistical associations derived from group comparisons may illuminate aspects of causality without fully capturing its richness.
The danger arises when a valuable method becomes elevated into an ideology. Evidence-based medicine originally sought to improve clinical decision-making by integrating research evidence, clinical expertise, and patient values. Over time, some interpretations have narrowed this vision into a hierarchy that privileges certain forms of evidence while marginalising others. Clinical judgement, biological plausibility, mechanistic understanding, and patient experience can become subordinate to a methodological framework that was never intended to bear such weight.
The randomised controlled trial remains one of medicine's most important achievements. It has saved lives and exposed error. Yet it is neither infallible nor universally applicable.
Scepticism here is not anti-science but pro-truth. When billions ride on outcomes, human nature and institutional pressures predict corner-cutting. The RCT remains a powerful tool, but like any instrument, its value depends on the hands wielding it, and the safeguards ensuring integrity. Until the Big Pharma tricks diminish and transparency reigns, healthy doubt serves patients better than uncritical acceptance.
https://www.vigilantfox.com/p/how-big-pharma-rigs-clinical-trialsand